dofetilide
DISEASE INTERVENTION COMPARISON RESULTS
Ugeskr Laeger. 2000 Oct 30;162 (44);5948-53 Randomized Controlled Trial
IN StudyID: DIAMOND 2001 (subordinated publication), atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization, heart failure - at 1 year
N Engl J Med. 1999 Sep 16;341(12):857-65 Randomized Controlled Trial, Multicenter Trial
IN StudyID: DIAMOND 2001 (subordinated publication), atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization, heart failure - at 18 months
Congest Heart Fail. 2001 May-Jun;7(3):146-150 Randomized Controlled Trial, Multicenter Trial
IN StudyID: DIAMOND 2001 (subordinated publication), atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization because heart failure, adverse effects, proarythmia - at 12 months
Circulation. 2001 Jul 17;104(3):292-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: DIAMOND 2001, atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization, heart failure - at 12 months
Drugs. 1999 Dec;58(6):1043-59 Review (Narrative)
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
J Am Coll Cardiol. 2000 Feb;35(2 Suppl. A):154A-155A Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To mortality at 1 year
Circulation. 1998 Oct 27;98(17):66 Suppl. 13-14 Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Circulation. 1998 Oct 27;98(17):3326 Suppl. I-633 Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Accessed 2010 August 10 at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-931_Tikosyn.cfm Randomized Controlled Trial
IN StudyID: EMERALD 1998, atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To reduce, at 1 year, AF recurrence. But they did not modified mortality and both increased adverse events and pro-arrhythmia
Circulation. 2000 Nov 7;102(19):2385-90 Randomized Controlled Trial, Multicenter Trial
IN StudyID: SAFIRE 2000, atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, proarrhythmia - at 12 months
Ital Heart J 2001 Mar;2(3 Suppl):322-3 Randomized Controlled Trial
IN StudyID: Vergara 2001 (get full text), atrial fibrillation The Use of
dofetilide
As Treatment, Chronic
Is - Than
Not available
To Not available